Award Year / Program / Phase:2009 / SBIR / Phase I
Agency:HHS
Principal Investigator:John S. Chant
Award Amount:$692,326.00
Abstract:
DESCRIPTION (provided by applicant): Hematologic toxicity is a principal cause of morbidity and mortality after exposure to ionizing radiation (IR). G-Zero Therapeutics, with operations in the Research Triangle Park, North Carolina, has developed a nov
el approach to mitigating the hematologic… More
Award Year / Program / Phase:2011 / SBIR / Phase II
Agency:HHS
Principal Investigator:Jay C. Strum – 919-966-9755
Award Amount:$3,000,000.00
Abstract:
DESCRIPTION (provided by applicant): Syndrome (ARS), including a lethal myelosuppression due to the sensitivity of proliferating hematopoietic stem/progenitor cells (HSPCs) to ionizing radiation (IR). No effective therapy exists to mitigate the hematologictoxicities of TBI. Herein G-Zero… More